Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer

BACKGROUND: Crizotinib has been the standard treatment for patients with anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). It demonstrated superior progression-free survival (PFS) and higher objective response rates (ORRs) vs. chemotherapy in previously treated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Del Valle, Maria Fatima Flores, Chang, Alex Yuang-Chi
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790458/
https://ncbi.nlm.nih.gov/pubmed/31656659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.09.15
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados